Topas Therapeutics is a clinical-stage biotechnology company that develops TPCs (Topas Particle Conjugates) to address major unmet needs in T-cell mediated diseases. TPCs are uniquely engineered to restore and promote immune tolerance by targeting liver sinusoidal endothelial cells (LSECs) and harnessing antigen-specific immune tolerance mechanisms of the liver. The company's technology has delivered two clinical candidates, TPM203 and TPM 502, which are in Phase 1 and Phase 2 clinical trials, respectively, for pemphigus vulgaris and celiac disease.